# Progress Note 06 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN-TD
- Date: 1885-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Video visit for the six-month kidney review. **S**

## History of present illness

Ms. Dickinson is seen by video from her home; the mobile phlebotomy service drew blood and collected a urine sample this morning, and she measured her vital signs with her own devices before the call. She feels well, with no headaches since the spring. Her home blood pressure averages 118/72. She takes losartan 100 mg, dapagliflozin 10 mg, amlodipine 5 mg, atorvastatin 20 mg, and vitamin D3 daily and has taken no NSAIDs. She has had no lightheadedness, ankle swelling, urinary symptoms, or muscle aches. She would like her second hepatitis B dose and her influenza vaccine at her preventive visit next month, so that she makes one trip. **S**

| Element | Detail |
|---|---|
| Visit format | Video visit from home, with home-measured vital signs and a home blood and urine collection |
| Symptoms | No headaches since the spring |
| Home blood pressure | Average 118/72 mmHg |
| Medication tolerance | No lightheadedness, edema, urinary symptoms, or muscle aches |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No ankle swelling or lightheadedness |
| Genitourinary | Negative | No urinary symptoms or genital itching |
| Neurological | Negative | No headaches |

3 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/74 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 53.4 kg; BMI 20.1 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.6 mmol/L; Bicarbonate (total CO2): 25 mmol/L; BUN: 21 mg/dL; Creatinine: 1.28 mg/dL (high); eGFR: 50 mL/min/1.73 m² (low); Glucose: 90 mg/dL; Urine albumin-creatinine ratio: 96 mg/g (high); Calcium: 9.4 mg/dL; Phosphate: 3.6 mg/dL; Intact PTH: 61 pg/mL; 25-hydroxyvitamin D: 36 ng/mL. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Bicarbonate (total CO2): 24 mmol/L at baseline, 25 mmol/L at this visit **S**
- BUN: 21 mg/dL at baseline, 21 mg/dL at this visit **S**
- Creatinine: 1.2 mg/dL (high) at baseline, 1.28 mg/dL (high) at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 50 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 90 mg/dL at this visit **S**
- Urine albumin-creatinine ratio: 240 mg/g (high) at baseline, 96 mg/g (high) at this visit **S**
- Calcium: 9.3 mg/dL at baseline, 9.4 mg/dL at this visit **S**
- Phosphate: 3.8 mg/dL at baseline, 3.6 mg/dL at this visit **S**
- Intact PTH: 74 pg/mL (high) at baseline, 61 pg/mL at this visit **S**
- 25-hydroxyvitamin D: 21 ng/mL (low) at baseline, 36 ng/mL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General (video) | Well and animated; respiratory rate 14 counted on video |
| Extremities (video) | No pitting seen when she pressed on her shins |
| Mental status (video) | Alert and engaged; euthymic |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3a A2** (N18.31). Creatinine 1.28 mg/dL (eGFR 50) and potassium 4.6 mmol/L, stable. Urine albumin-creatinine ratio 96 mg/g, still falling. **S**
   - Continue current treatment.
   - eGFR, urine albumin, hemoglobin, and KFRE in January; a video update with nephrology at about that time, as Dr. Adeyemi advised.
2. **Vitamin D deficiency** (E55.9). 25-hydroxyvitamin D 36 ng/mL and PTH 61 pg/mL, now in range; calcium 9.4 and phosphate 3.6 mg/dL. **S**
   - Continue vitamin D3 1,000 units daily.
   - Recheck calcium, phosphate, and PTH in 6 to 12 months.
3. **Hypertension with chronic kidney disease** (I12.9). 118/74 mmHg on her home cuff; home average 118/72, at the KDIGO target. **S**
   - No change.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | eGFR with metabolic panel | Twice a year at G3a A2 (KDIGO heat map) | Completed today | Potassium 4.6 mmol/L, creatinine 1.28 mg/dL, eGFR 50 |
| Laboratory | Urine albumin-creatinine ratio | Twice a year at G3a A2 (KDIGO heat map) | Completed today | 96 mg/g, down from 240 at intake |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months at G3a | Completed today | Calcium 9.4 mg/dL, phosphate 3.6 mg/dL, PTH 61 pg/mL |
| Laboratory | 25-hydroxyvitamin D after repletion | At baseline; repeated according to level and treatment | Completed today | 36 ng/mL on vitamin D3 |
| Examination | Standardized home blood pressure on a validated cuff | Every visit | Completed today | 118/74 mmHg today; home average 118/72 |
| Examination | Weight | Every visit | Completed today | 53.4 kg on her home scale |
| Examination | Cardiac auscultation | Every visit | Deferred | Not possible at a video visit; no cardiac symptoms. Done at the June home visit and planned at next month's preventive visit |
| Examination | Fundoscopic examination | Yearly in chronic hypertension | Due | Planned at next month's preventive visit |
| Laboratory | Hemoglobin and KFRE | Yearly in G3 | Up to date | Hemoglobin 12.3 g/dL and KFRE 0.5 and 1.6 percent in January; due again in January |
| Laboratory | Lipid panel | Once at diagnosis (KDIGO); yearly in the CMID hypertension schedule | Not indicated | On atorvastatin for chronic kidney disease; KDIGO advises no routine repeat lipid testing |
| Medication safety | Medication review: NSAID avoidance, SGLT2 inhibitor and statin safety | Every visit | Completed today | No NSAIDs; no genital, urinary, or muscle symptoms |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Due | HepB-CpG dose 2, influenza, and zoster dose 1 planned at next month's preventive visit, at her request, to avoid an extra trip; dose 2 remains well within the schedule |
| Self-management | Sodium, activity, and home readings | Every visit | Completed today | Low-salt cooking; garden work most afternoons |

## Goal progress

- Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness. Outcome by 1885-09-28: 118/74 mmHg on losartan 100 mg and amlodipine 5 mg. **S**
- Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor. Outcome by 1885-06-01: 118 mg/g at three months and 96 mg/g at six months, from 240 mg/g. **S**
- Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip. Outcome by 1885-09-28: eGFR 50 at the six-month review (54 at baseline); a temporary fall to 36 during gastroenteritis recovered. **S**
- 25-hydroxyvitamin D of at least 30 ng/mL. Outcome by 1885-09-28: 36 ng/mL on vitamin D3; PTH 61 pg/mL. **S**
- Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic. Outcome by 1885-09-28: Two clinic trips in the episode, each combining several tasks; all other visits at home or by video. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney Int 2021;99(3S):S1-S87)
- 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017), American College of Cardiology and American Heart Association (Hypertension 2018;71(6):e13-e115)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026), Aether Forge

## Follow-up

- Preventive visit at the clinic next month. Yearly kidney tests and review in January. **S**
- Next scheduled visit 1885-10-19: periodic adult preventive visit. **S**
